<DOC>
	<DOCNO>NCT00704964</DOCNO>
	<brief_summary>The objective study assess impact participant care support treatment adherence . PegIntron pen Rebetol administer participant Hepatitis C Virus ( HCV ) accordance approve label . Sites categorize provide high v low level participant management base information level participant support management capture site questionnaire . Data participant collect physician electronic participant case report form ( CRF ) participant via questionnaire . Treatment completion rate analyze base high v low level participant management . The hypothesis Physicians investing time effort participant management achieve high treatment completion rate among hepatitis C patient physicians offer less participant management measure .</brief_summary>
	<brief_title>Impact Patient Support Medical Staff Adherence Therapy With PegIntron Plus Rebetol ( Study P04413 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Participants chronic hepatitis C. Those participate patient assistance program therapy hepatitis C. Participants previously treatment hepatitis C ( nonna√Øve ) Other exclusion criterion describe local Summary Product Characteristics ( SPC ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>